Keyphrases
Acquired Epilepsy
9%
Antiepileptogenic
19%
Astrocytes
27%
Brain Injury
11%
Cellular Mechanisms
7%
Cerebrospinal Fluid
9%
Cortex
7%
Cortical Malformation
8%
Dendritic Injury
8%
Dendritic Spines
13%
Dentate Gyrus
7%
Drug-resistant Epilepsy
7%
Electroencephalography
8%
Epilepsy
83%
Epilepsy Model
6%
Epilepsy Syndrome
6%
Epilepsy Treatment
12%
Epileptogenesis
49%
Estrogen
6%
Focal Cortical Dysplasia
9%
Genetic Epilepsy
9%
Glia
7%
Hippocampus
8%
Infantile Spasms
6%
Kainate
10%
Knock-in Mouse Model
11%
Leptin
6%
Malformations of Cortical Development
11%
Mammalian Target of Rapamycin (mTOR)
40%
Mammalian Target of Rapamycin Inhibition
7%
Mammalian Target of Rapamycin Pathway
22%
Microglia
6%
Mouse Model
53%
MTOR Inhibitor
21%
Neuronal Ceroid Lipofuscinosis
6%
Neuronal Death
8%
Pathophysiology
9%
Pathway Activation
6%
Pentylenetetrazole-induced Seizures
7%
Post-traumatic Epilepsy
8%
Rapamycin
24%
REM Sleep
6%
Rodents
6%
Seizure
83%
Signaling Pathway
6%
Spontaneous Seizures
7%
TSC1
26%
Tuberous Sclerosis
20%
Tuberous Sclerosis Complex
100%
Vigabatrin
6%
Neuroscience
4-Aminopyridine
7%
Actin
11%
Astrocyte
30%
Cell Signaling
5%
Cognitive Disorders
5%
Dendrite
6%
Dendritic Spine
14%
Dentate Gyrus
8%
Dysplasia
7%
Epileptogenesis
44%
Excitability
5%
GABAA Receptor
5%
Gene Inactivation
5%
Glia
6%
Glutamic Acid
9%
Hippocampus
12%
Hypothalamus
5%
In Vitro
9%
In Vivo
16%
Intellectual and Developmental Disabilities
5%
Interneuron
5%
Intractable Epilepsy
5%
Ion Channel
5%
Leptin
6%
Mammalian Target of Rapamycin
45%
Microglia
7%
Neuronal Cell Death
9%
Neurotransmitter
9%
Neurotrauma
6%
Pentylenetetrazol
5%
Post-Traumatic Epilepsy
8%
Protein Biosynthesis
5%
Receptor
7%
Sirolimus
23%
Status Epilepticus
7%
Synaptic Transmission
6%
Traumatic Brain Injury
6%
TSC1
8%
Tuberous Sclerosis
79%
Vertebral Column
8%
Vigabatrin
6%